AAP
DNTH icon

Arax Advisory Partners’s Dianthus Therapeutics DNTH Stock Holding History

Arax Advisory Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$420 Buy
5
+4
+400% +$232 ﹤0.01% 3442
2025
Q4 		$41 Sell
1
-52
-98% -$2.02K ﹤0.01% 3951
2025
Q3 		$2.09K Buy
+53
New +$1.35K ﹤0.01% 3106
2025
Q2 		– Sell
-32
Closed -$581 – 3086
2025
Q1 		$581 Hold
32
– – ﹤0.01% 2515
2024
Q4 		$698 Buy
+32
New +$823 ﹤0.01% 2251

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Arax Advisory Partners's DNTH Position: Q1 2026 in Review

Arax Advisory Partners increased its Dianthus Therapeutics (DNTH) stake by 400% in Q1 2026, buying an estimated $232 and bringing the position to 5 shares worth $420. The position accounts for ﹤0.01% of the portfolio, ranked #3442.

Arax Advisory Partners first reported a position in DNTH in Q4 2024 and has held it in 5 quarters since. The position peaked at $2.09K in Q3 2025. 241 funds tracked by Wall St. Rank hold DNTH as of Q1 2026.

  • Arax Advisory Partners held 5 shares of Dianthus Therapeutics worth $420 as of Q1 2026.
  • Arax Advisory Partners bought 4 Dianthus Therapeutics shares in Q1 2026, an estimated $232.
  • Dianthus Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3442 holding.
  • Arax Advisory Partners first reported a position in Dianthus Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • Arax Advisory Partners's Dianthus Therapeutics position peaked at $2.09K in Q3 2025.
  • 241 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.